Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $91 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.